Tag
A cohort of 432 children with Graves disease found 24% developed neutropenia on methimazole, mostly within the first month. TPOAb-negative status and younger age increased risk.
A randomized trial reveals that adding L-carnitine and selenium to methimazole therapy significantly accelerates TRAb negativity, increases remission rates, and reduces cumulative drug exposure in patients with Graves’ disease.
A recent randomized trial shows that supplementing methimazole with L-carnitine and selenium in Graves’ disease shortens disease duration, lowers antibody levels faster, reduces medication dose, and improves select symptoms, highlight
